PCOS Hair Loss: What Your Blood Work Can Tell You
PCOS Hair Loss:
What It Looks Like
And What Your Blood Work Can and Cannot Tell You.
When a woman tells me her part is getting wider, polycystic ovary syndrome is often the first explanation she has already heard. It is a real cause, and it is a common one. It is also surrounded by inflated numbers and one claim that leaves many women more confused after their blood test than before it. This is what the research actually says, including the part most pages skip.
PCOS can cause hair loss on the scalp. It shows up as female pattern hair loss: a part that widens and thinning across the top of the head, usually with the front hairline kept.[3][7] In the research, it affects roughly one in five to three in ten women with PCOS, not the 40 to 70% repeated online.[2][3][12] The part almost nobody explains: in a specialist PCOS clinic, the women with hair loss showed no difference in blood androgen results from the women without it.[2] That is why the expert panel says thinning hair on its own does not prove a hormone problem, and also that every woman with it should have her androgens checked.[3] A normal result does not mean nothing is happening. Topical minoxidil is the first-line treatment, and prescription options belong with your doctor.[3]
- What PCOS hair loss actually is
- How common it really is
- Two statements that sound like a contradiction
- Why your blood work can come back normal
- How PCOS is actually diagnosed
- What it looks like on the scalp
- What the evidence says about treating PCOS hair loss
- What the top search results leave out
- Compared with other causes of thinning
- What happens at a scalp evaluation
- The evidence behind this article, graded
- Frequently asked questions
What PCOS Hair Loss Actually Is
Polycystic ovary syndrome is a common hormonal disorder. The World Health Organization describes it as one in which higher than normal androgen levels lead to irregular periods, abnormal ovulation, infertility, excess facial or body hair, and acne.[1] It affects an estimated 10 to 13% of women of reproductive age, and WHO estimates that up to 70% of women with PCOS worldwide do not know they have it.[1]
Hair loss on the scalp is part of that picture, although it is easy to miss. The short “key facts” list at the top of the WHO page names facial and body hair and acne, and not the scalp. Scalp thinning appears further down, among the symptoms (“female-pattern baldness or hair thinning”) and in the diagnostic signs of high androgens (“loss of hair from the head”).[1]
The hair loss itself is female pattern hair loss. In 2019 the multidisciplinary committee of the Androgen Excess and PCOS Society asked that this term be used, avoiding the older terms alopecia and androgenetic alopecia.[3] You will still see “androgenic alopecia” in older research, including one of the main studies below. It describes the same condition.
What happens in the follicle is a slow shrinking rather than a sudden shed. The committee names the key features as a shortened growing phase and miniaturization of the follicles in the affected scalp.[3] Each new hair grows back finer and shorter than the one before it. On a healthy scalp, roughly 80 to 90% of hairs are in the growing phase, which lasts two to six years.[7] As that phase shortens, the hair never reaches its old length or thickness, and the scalp starts to show through.
The same process runs in men and women, but it runs less completely in women. The committee's explanation is that the miniaturization is not as profound, and not every hair in the affected area is involved equally.[3] That is why PCOS hair loss shows as thinning rather than bare scalp. It is also why it is so easy to talk yourself out of. Thinning that is gradual and partial is still thinning, and the 2023 international guideline asks doctors to treat a woman's report of hair loss as important regardless of apparent clinical severity.[4]
How Common It Really Is
This is the number most pages get wrong, so I want to go straight to the studies.
The most careful single study comes from a multidisciplinary PCOS clinic at a university center in San Francisco. Between 2007 and 2012, 254 women who met the Rotterdam criteria for PCOS were each examined by a reproductive endocrinologist, a dermatologist and a psychologist. Fifty-six of them, 22.0%, had pattern hair loss.[2]
The Androgen Excess and PCOS Society committee then pooled nine studies and arrived at 28%, with a range of 22 to 34%. Its own summary is more cautious: the data are few and highly variable, and pattern hair loss is found in 20 to 30% of women with PCOS.[3] Only one of those studies compared women with PCOS against women without it. It found pattern hair loss in 23.1% of the PCOS group against 8.8% of age-matched controls.[3]
The question also runs the other way. A hair loss clinic at Massachusetts General Hospital reviewed 472 women diagnosed with female pattern hair loss between 2017 and 2019. Thirty-eight of them (8%) already knew they had PCOS. Fifteen more were referred to reproductive endocrinology, mostly because their periods were irregular, and 12 of those 15 were diagnosed with PCOS.[6] Taken together, that is about 50 of the 472 women, roughly one in nine.
All three figures come from specialist clinics, where women arrive because something is already wrong, so none of them describes every woman with PCOS. The committee graded its own prevalence estimate at level C on its A-to-D scale.[3] The San Francisco study notes that the definition of PCOS changes the answer: criteria that require high androgens would be expected to produce a higher figure than the Rotterdam criteria it used.[2] And the Massachusetts study was small and looked back through records.[6] The honest summary is roughly one in five to three in ten, not a precise figure.
Two Statements That Sound Like a Contradiction
This is the finding I most want every woman with PCOS to hear, and the rest of this article turns on it.
In the San Francisco study, the women with hair loss were more likely to have acne or excess body hair as well: 96.3% against 70.6%. But when the researchers compared their blood work, they found: “There were no differences between subjects with and without AGA in biochemical hyperandrogenism or metabolic parameters.”[2] The women losing their hair did not have higher androgen levels in their blood than the women who were not.
The same study measured how the women felt about it. 70.4% of the women with hair loss were concerned about their hair, against 37.7% of the women without it.[2] Their depression screening scores were no different, but the worry was plainly there.
Now set two of the expert committee's recommendations side by side. The first: “Isolated FPHL should not be considered a sign of hyperandrogenism when androgen levels are normal and no other clinical signs of hyperandrogenism are present.” The second: “In all patients with FPHL, assessment of a possible androgen excess is mandatory.”[3]
Read quickly, those seem to cancel each other out. They do not. The first says that thinning hair by itself is not proof of a hormone problem. The second says that because it might be one, it always deserves the check. The 2023 international guideline lands in the same place from a different direction. It calls pattern hair loss and acne without excess body hair “relatively weak predictors of biochemical hyperandrogenism.” Yet the same guideline asks doctors to look for them in every woman being assessed for PCOS.[4] The Endocrine Society's earlier guideline said much the same: some studies found that acne and pattern hair loss are not good markers of high androgens in PCOS, compared with excess body hair.[5]
If your androgen results come back normal, you are not imagining your hair loss, and the test did not fail. Pattern hair loss can be present without any detectable sign of androgen excess, and the committee rates that finding at level B, a higher grade than it gives its own prevalence estimate.[3] Now the counter-evidence: normal androgens do not rule PCOS out either, because PCOS can be diagnosed without high blood androgens, as the next two sections explain.[4] And the committee is open that the link between androgens and pattern hair loss in women remains unclear.[3] A normal result answers one question. It does not answer the whole thing.
Why Your Blood Work Can Come Back Normal
There are at least four reasons.
First, some women with PCOS never show high androgens in the blood. PCOS can be diagnosed without them, as the next section explains.[4]
Second, the follicle may respond to androgens that a blood test does not see. A 2020 review of hormones and hair explains that androgen action in the scalp can be stronger because of more activity of 5-alpha reductase, the enzyme that makes the more potent androgen DHT, or because of how androgens bind to receptors in the follicle.[15] A blood test measures what circulates, not what happens inside the follicle. For any one woman that remains a possibility, not something a test can confirm.
Third, “normal” is a softer line than it looks. The 2023 guideline points out that laboratory reference ranges vary widely and are often drawn from populations that are “highly likely to include women with PCOS.”[4] The method matters too. The guideline asks laboratories to use tandem mass spectrometry for testosterone rather than direct immunoassays, which it describes as having limited accuracy and poor sensitivity for diagnosing high androgens in PCOS.[4]
Fourth, the pill changes the result. The combined oral contraceptive pill raises the protein that binds testosterone and lowers the ovaries' androgen output, so the guideline says it is “very difficult” to reliably assess androgens in women taking it. Where testing is essential, it says the pill should be stopped for a minimum of three months first, with contraception managed another way in the meantime.[4] That is a decision to make with your doctor, never on your own.
How PCOS Is Actually Diagnosed
Many women assume PCOS is confirmed or ruled out by a hormone test. It is not. Under the 2023 international guideline, adult women are diagnosed when two of these three are present, after other causes have been excluded:[4]
High androgens, in the body or the blood
Clinical signs such as excess body hair, acne or pattern hair loss, or high androgens on a blood test. Either counts.[4]
Irregular or absent ovulation
Usually seen as irregular periods. In the Massachusetts hair clinic, irregular periods were what most often led to a referral.[1][4][6]
Polycystic ovaries
Seen on ultrasound, or since 2023, a blood level of anti-Müllerian hormone (AMH) can be used instead.[4]
A stricter rule
Adolescents need both high androgens and irregular ovulation. Ultrasound and AMH are not recommended for them because they are not specific enough.[4]
Two things follow from that. A woman with irregular periods and polycystic ovaries has PCOS even if her androgen tests are completely normal. And because clinical signs count toward the first criterion, pattern hair loss itself can be part of the evidence. In the Massachusetts study, serum hormone levels were not needed for any of the 12 new diagnoses.[6]
When blood tests are used, the guideline says to start with total and free testosterone, with free testosterone often estimated as a free androgen index. If those are not raised, androstenedione and DHEAS can be considered, with the caveat that they are less specific.[4] The expert committee adds that vitamin D, iron, zinc, thyroid hormones and prolactin are optional but recommended in women with pattern hair loss, to find other conditions that can affect regrowth.[3]
What It Looks Like on the Scalp
The committee describes two typical patterns: thinning that spreads outward from the middle of the scalp, and a frontal accentuation, sometimes called the Christmas tree pattern.[3]
The American Academy of Dermatology describes what most women notice first: the part often gets wider, and hair near the temples may recede.[8] The clinical reference from the National Library of Medicine adds the detail that separates it from male balding: in women, the front hairline is typically kept, with diffuse thinning at the crown and top of the head.[7]
Doctors grade it on visual scales. The 2023 guideline suggests the Ludwig or Olsen scales.[4] If you have been told your hair “looks fine,” remember that the same guideline asks doctors to take hair loss seriously regardless of apparent clinical severity.[4] You are often the first to see it, because you know what your part used to look like.
Pattern thinning often becomes visible all at once rather than gradually. The clinical reference notes that in women, pattern hair loss is often unmasked by telogen effluvium, a diffuse shed that follows a stressor by one to six months.[7] Losing a lot of hair at once removes the coverage that was hiding a widening part. When the shed ends, the pattern loss is still there. If your hair “never came back properly” after an illness, a birth or a stressful stretch, that is worth having looked at.
What the Evidence Says About Treating PCOS Hair Loss
Treatment for PCOS hair loss is largely treatment for female pattern hair loss, and I would rather be honest that the evidence is thinner than most pages admit. The 2023 international guideline is candid about it: anti-androgens combined with the pill could be tried for pattern hair loss because of its psychological impact, “acknowledging the lack of evidence in the PCOS population.”[4]
How well do the anti-androgens work? The best-known study treated 80 women with pattern hair loss with spironolactone or cyproterone acetate. 44% had regrowth, 44% had no clear change, and 12% continued to lose hair.[9] Notably, their blood hormone levels did not predict who responded.[9] The study had no placebo group, and its own authors say one is needed, because pattern hair loss can hold steady for a time on its own. The women in it were not selected for PCOS.[9]
Starting minoxidil can cause a temporary increase in shedding.[7] How long it lasts depends on who you ask. The AAD says two to eight weeks.[8] The FDA-reviewed label on at least one women's 5% foam says hair loss “may continue for up to 2 weeks,” and to see a doctor if it continues after that.[11] Either way, a shed in the first weeks is not a reason to stop on your own. Talk to whoever recommended it.
Two things I want to say plainly. Never stop a prescribed medication on your own, including the pill or spironolactone, because your hair seems worse or better; that is a conversation with the doctor who prescribed it. Spironolactone in particular should be avoided in pregnancy because of the potential risk to a male fetus.[10] And no controlled trial of any Kapyderm product in PCOS-related hair loss exists. Kapyderm sells scalp care, and I would rather write that down than let anyone think a shampoo or serum is a substitute for the medical side of this.
What the Top Search Results Leave Out
Before writing this, I read the pages that rank at the top of Google for PCOS hair loss. Two things stood out.
The numbers are inflated, or missing a source. One of the top results, a physician's guide, says reports of pattern hair loss in PCOS “vary from a prevalence of 40-70%”.[12] A PCOS nutrition site says it affects “approximately 40-70% of women.”[13] A dermatology practice says “About 10%.”[14] The first two give no source for their figure. The third links to the Massachusetts study above, but that study answered the reverse question: how many women with pattern hair loss had PCOS, not how many women with PCOS have pattern hair loss.[6] The clinic studies and the expert committee's pooled review put it at roughly 20 to 30%.[2][3]
Not one of them tells you your blood work may come back normal. Several imply the opposite, describing PCOS hair loss as the result of the body producing too many androgens. That is the most harmful gap. A woman is told her thinning hair means a hormone problem, her test comes back normal, and she is left thinking either the test is wrong or she is. The research says neither is true.[2][3]
Compared With Other Causes of Thinning
Three things produce thinning across the top of the scalp in women, and they are told apart by how they start, where the hair goes, and what the blood work shows.
| Feature | Pattern loss with PCOS | Pattern loss without PCOS | Telogen effluvium (a shed) |
|---|---|---|---|
| How it starts | Gradually, during the reproductive years | Gradually, most often from the 40s on | Suddenly, one to six months after a stressor |
| Where it shows | Widening part, top of the scalp, front hairline kept | Widening part, top of the scalp, front hairline kept | Diffuse, across the whole scalp |
| Blood androgens | Can be raised, or normal | Often normal | Not the cause |
| Other signs | Irregular periods, acne, excess body hair | Family history; more common after menopause | A recent illness, birth or major stressor |
| Where it goes | Does not resolve on its own; treatment slows or partly reverses it | Does not resolve on its own; treatment slows or partly reverses it | Can uncover pattern loss that was already there |
The first two columns look identical on the scalp, which is the point. What separates them is the rest of the history: periods, skin, body hair and, where it is needed, blood work and an ultrasound.[3][4] Pattern loss that comes with androgen excess usually starts in young adulthood, while for most women without it, it begins in their 40s, 50s or 60s and is more common after menopause.[15][8] A woman in her twenties with a widening part and irregular periods is a different conversation from a woman in her sixties with the same part. The shed column draws on the clinical reference cited above.[7]
What Happens at a Scalp Evaluation
A scalp evaluation does not diagnose PCOS, and I never present it as one. What it can do is show what is happening at the follicle, and record it.
Under magnification, which is how I look at every scalp, pattern hair loss has a recognizable look: hairs of visibly different thickness in the affected area, because not every follicle shrinks to the same degree.[3] In the San Francisco study, pattern hair loss was defined by exactly that, miniaturization in a characteristic pattern, either diffuse or with frontal accentuation.[2] None of it can be judged from a photo of a hairbrush.
The part I care most about is the record. Density and hair-thickness variation written down at one visit give the next visit something to compare against, which matters for a treatment that takes six to 12 months to judge.[8] The 2023 guideline asks doctors to monitor pattern hair loss for improvement during treatment, and a measured baseline is how that is done.[4]
A trichological evaluation is an assessment of the scalp and hair rather than a medical diagnosis. Where the picture points at a hormonal cause, especially pattern thinning with irregular periods, acne or excess body hair, the right outcome of my appointment is a referral to a physician. That is exactly what the Massachusetts researchers concluded: women who come to a dermatologist with hair loss “should be considered for RE referral”, meaning reproductive endocrinology.[6]
The Evidence Behind This Article, Graded
Not every claim above rests on the same quality of evidence, and pretending otherwise is how hair-loss writing loses its credibility. Here is what each one is actually standing on.
Reasonably supported, imprecise
One well-designed clinic study found 22%,[2] and a pooled review of nine studies found 28%, which its authors graded at level C and summarized as 20 to 30%.[3] The limit: every figure comes from specialist clinics, and the definition of PCOS used changes the answer.[2]
Well supported
Directly observed in the San Francisco clinic,[2] rated level B by the expert committee,[3] and consistent with the 2023 guideline calling pattern hair loss a weak predictor of high blood androgens.[4] The limit: the guideline rates its own certainty on that point as very low, and why it happens is still a hypothesis.[4][15]
Expert consensus
Stated as mandatory by the Androgen Excess and PCOS Society committee,[3] which graded the underlying advice to measure circulating androgens at level C. It is a recommendation from experts reviewing limited data, not the result of a trial.
Well supported
Level B in the committee's review,[3] and FDA-approved for female pattern hair loss at 2% and 5%.[8] The limit: that evidence is for pattern hair loss in general, not for women with PCOS specifically.
Plausible, weakly tested
Level C in the committee's review.[3] The best-known study had no placebo group and did not select for PCOS,[9] and the 2023 guideline names the lack of evidence in the PCOS population outright.[4] None of these medicines is FDA-approved for hair loss.[8][10]
The honest gaps
Nobody knows how many women in the general population have PCOS-related hair loss, because every study comes from a clinic. The strength and nature of the link between androgens and pattern hair loss in women remains unclear, in the committee's own words.[3] There is no placebo-controlled trial of any treatment for pattern hair loss in women with PCOS specifically, and the 2023 guideline's recommendation on treating it is a consensus recommendation made in the absence of adequate evidence.[4] Everything above about treatment is borrowed from studies of pattern hair loss in general, and should be read that way.
Frequently Asked Questions
- World Health Organization. “Polycystic ovary syndrome” fact sheet. who.int. 22 January 2026. Source for the 10 to 13% prevalence, the estimate that up to 70% of women with PCOS do not know they have it, scalp hair loss among the symptoms and diagnostic signs, and the treatment section, which does not mention scalp hair.
- Quinn M, Shinkai K, Pasch L, Kuzmich L, Cedars M, Huddleston H. Prevalence of androgenic alopecia in patients with polycystic ovary syndrome and characterization of associated clinical and biochemical features. Fertility and Sterility. 2014;101(4):1129–1134. doi:10.1016/j.fertnstert.2014.01.003. PMID 24534277. Cross-sectional study of 254 women meeting the Rotterdam criteria at a multidisciplinary PCOS clinic at a tertiary academic center, examined 2007 to 2012. The authors note that classifying clinical hyperandrogenism is somewhat subjective and that minoxidil use was not systematically recorded.
- Carmina E, Azziz R, Bergfeld W, Escobar-Morreale HF, Futterweit W, Huddleston H, Lobo R, Olsen E. Female Pattern Hair Loss and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee. Journal of Clinical Endocrinology & Metabolism. 2019;104(7):2875–2891. doi:10.1210/jc.2018-02548. PMID 30785992. Systematic review of studies published through December 2017, with evidence graded A to D; pooled prevalence of 28% (95% CI, 22% to 34%) across nine studies. The authors report nothing to disclose. One author (Huddleston) also co-authored reference 2.
- Teede HJ, Tay CT, Laven JJE, Dokras A, Moran LJ, Piltonen TT, Costello MF, Boivin J, Redman LM, Boyle JA, Norman RJ, Mousa A, Joham AE. Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Journal of Clinical Endocrinology & Metabolism. 2023;108(10):2447–2469. doi:10.1210/clinem/dgad463. PMID 37580314. Primarily funded by the Australian National Health and Medical Research Council, in partnership with the American Society for Reproductive Medicine, the Endocrine Society, the European Society of Human Reproduction and Embryology, and the European Society of Endocrinology.
- Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, Welt CK. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism. 2013;98(12):4565–4592. doi:10.1210/jc.2013-2350. PMID 24151290. Cited for its statement that acne and pattern hair loss are not good markers of high androgens in PCOS compared with excess body hair.
- Prasad S, De Souza B, Burns LJ, Lippincott M, Senna MM. Polycystic ovarian syndrome in patients with hair thinning. Journal of the American Academy of Dermatology. 2020;83(1):260–261. doi:10.1016/j.jaad.2020.01.075. PMID 32444272. Retrospective review of 472 women with female pattern hair loss at a Massachusetts General Hospital hair loss clinic, January 2017 to June 2019. The authors list the small sample and retrospective design as limitations.
- Ho CH, Sood T, Zito PM. Androgenetic Alopecia. In: StatPearls. Treasure Island (FL): StatPearls Publishing. ncbi.nlm.nih.gov. NCBI Bookshelf ID NBK430924. Last updated January 7, 2024. Clinical reference for the hair cycle, how pattern hair loss presents in women, unmasking by telogen effluvium one to six months after a stressor, and the initial shedding phase when treatment starts.
- American Academy of Dermatology Association. “Thinning hair and hair loss: Could it be female pattern hair loss?” aad.org. Last updated 12/13/22. Source for the widening part, FDA approval of 2% and 5% minoxidil for female pattern hair loss, the two-to-eight-week early shed, six to 12 months to judge treatment, spironolactone use and its timeline, and the evidence on shampoos and supplements.
- Sinclair R, Wewerinke M, Jolley D. Treatment of female pattern hair loss with oral antiandrogens. British Journal of Dermatology. 2005;152(3):466–473. doi:10.1111/j.1365-2133.2005.06218.x. PMID 15787815. Single-center, open, before-and-after study of 80 women aged 12 to 79 with biopsy-confirmed miniaturization, treated with spironolactone 200 mg daily or cyproterone acetate. No placebo group; not limited to women with PCOS.
- Pfizer. ALDACTONE (spironolactone) tablets, prescribing information. DailyMed. Effective November 28, 2025. Source for the approved indications, which do not include hair loss, and the advice to avoid spironolactone in pregnancy because of the potential risk to a male fetus.
- Aurohealth. Women's Minoxidil Topical Aerosol 5% (Foam), drug label. DailyMed. Effective January 22, 2026. Source for the label statement that hair loss may continue for up to two weeks after starting. Not every minoxidil label carries this sentence.
- Futterweit W. “Management of Hair Loss in Polycystic Ovary Syndrome.” contemporaryobgyn.net. Quoted for its 40 to 70% prevalence range, which the page gives without an inline citation. Wording current as of October 4, 2026.
- PCOS Nutrition Center. “PCOS and Hair Loss: Effective Treatment Options.” pcosnutrition.com. Quoted for its 40 to 70% figure, which the page gives without an inline citation. Wording current as of October 4, 2026.
- Central Utah Dermatology. “The Link Between PCOS and Hair Loss.” centralutahdermatology.com. Quoted for its figure of about 10%, which the page links to reference 6, a study that measured the reverse question. Wording current as of October 4, 2026.
- Grymowicz M, Rudnicka E, Podfigurna A, Napierala P, Smolarczyk R, Smolarczyk K, Meczekalski B. Hormonal Effects on Hair Follicles. International Journal of Molecular Sciences. 2020;21(15):5342. doi:10.3390/ijms21155342. PMC7432488. Open-access review. Source for androgens stimulating facial and body hair while inhibiting scalp hair, enhanced androgen action in the scalp through 5-alpha reductase and DHT, and pattern hair loss with androgen excess usually starting in young adulthood.
Thinning Hair Deserves a Proper Look.
Even When the Blood Work Comes Back Normal.
If your part is widening, if thinning comes with irregular periods, acne or excess body hair, or if your hair never came back fully after a shed, that is worth an evaluation rather than another product. That is how I work, and it is how the Kapyderm specialists near you work: assess the scalp under magnification, record the numbers so the next visit has something to compare against, and refer to a physician when that is what the picture calls for.
